These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Discovery of novel orally active ureido NPY Y5 receptor antagonists. Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282 [TBL] [Abstract][Full Text] [Related]
3. Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds. Sakamoto T; Moriya M; Tsuge H; Takahashi T; Haga Y; Nonoshita K; Okamoto O; Takahashi H; Sakuraba A; Hirohashi T; Shibata T; Kanno T; Ito J; Iwaasa H; Gomori A; Ishihara A; Fukuroda T; Kanatani A; Fukami T Bioorg Med Chem; 2009 Jul; 17(14):5015-26. PubMed ID: 19525116 [TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs. Levens NR; Della-Zuana O Curr Opin Investig Drugs; 2003 Oct; 4(10):1198-204. PubMed ID: 14649211 [TBL] [Abstract][Full Text] [Related]
5. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity. Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450 [TBL] [Abstract][Full Text] [Related]
6. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice. Moriya R; Mashiko S; Ishihara A; Takahashi T; Murai T; Ito J; Mitobe Y; Oda Z; Iwaasa H; Takehiro F; Kanatani A Peptides; 2009 Jul; 30(7):1318-22. PubMed ID: 19394383 [TBL] [Abstract][Full Text] [Related]
7. Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists. Leslie CP; Bentley J; Biagetti M; Contini S; Di Fabio R; Donati D; Genski T; Guery S; Mazzali A; Merlo G; Pizzi DA; Sacco F; Seri C; Tessari M; Zonzini L; Caberlotto L Bioorg Med Chem Lett; 2010 Oct; 20(20):6103-7. PubMed ID: 20813523 [TBL] [Abstract][Full Text] [Related]
8. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Mashiko S; Ishihara A; Iwaasa H; Moriya R; Kitazawa H; Mitobe Y; Ito J; Gomori A; Matsushita H; Takahashi T; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A Obesity (Silver Spring); 2008 Jul; 16(7):1510-5. PubMed ID: 18421274 [TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Mashiko S; Moriya R; Ishihara A; Gomori A; Matsushita H; Egashira S; Iwaasa H; Takahashi T; Haga Y; Fukami T; Kanatani A Eur J Pharmacol; 2009 Aug; 615(1-3):113-7. PubMed ID: 19482021 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor. Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501 [TBL] [Abstract][Full Text] [Related]
11. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist. Omori N; Kouyama N; Yukimasa A; Watanabe K; Yokota Y; Tanioka H; Nambu H; Yukioka H; Sato N; Tanaka Y; Sekiguchi K; Okuno T Bioorg Med Chem Lett; 2012 Mar; 22(5):2020-3. PubMed ID: 22300657 [TBL] [Abstract][Full Text] [Related]
12. Novel series of substituted biphenylmethyl urea derivatives as MCH-R1 antagonists for the treatment of obesity. Galiano S; Ceras J; Cirauqui N; Pérez S; Juanenea L; Rivera G; Aldana I; Monge A Bioorg Med Chem; 2007 Jun; 15(11):3896-911. PubMed ID: 17407817 [TBL] [Abstract][Full Text] [Related]
13. Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor. Ando M; Sato N; Nagase T; Nagai K; Ishikawa S; Takahashi H; Ohtake N; Ito J; Hirayama M; Mitobe Y; Iwaasa H; Gomori A; Matsushita H; Tadano K; Fujino N; Tanaka S; Ohe T; Ishihara A; Kanatani A; Fukami T Bioorg Med Chem; 2009 Aug; 17(16):6106-22. PubMed ID: 19616955 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists. Sato N; Takahashi T; Shibata T; Haga Y; Sakuraba A; Hirose M; Sato M; Nonoshita K; Koike Y; Kitazawa H; Fujino N; Ishii Y; Ishihara A; Kanatani A; Fukami T J Med Chem; 2003 Feb; 46(5):666-9. PubMed ID: 12593644 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists. Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206 [TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand. Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648 [TBL] [Abstract][Full Text] [Related]
17. Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist. Haga Y; Sakamoto T; Shibata T; Nonoshita K; Ishikawa M; Suga T; Takahashi H; Takahashi T; Takahashi H; Ando M; Murai T; Gomori A; Oda Z; Kitazawa H; Mitobe Y; Kanesaka M; Ohe T; Iwaasa H; Ishii Y; Ishihara A; Kanatani A; Fukami T Bioorg Med Chem; 2009 Oct; 17(19):6971-82. PubMed ID: 19720539 [TBL] [Abstract][Full Text] [Related]
18. Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile. Tamura Y; Hayashi K; Omori N; Nishiura Y; Watanabe K; Tanaka N; Fujioka M; Kouyama N; Yukimasa A; Tanaka Y; Chiba T; Tanioka H; Nambu H; Yukioka H; Sato H; Okuno T Bioorg Med Chem Lett; 2013 Jan; 23(1):90-5. PubMed ID: 23206862 [TBL] [Abstract][Full Text] [Related]
19. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor. Fichtner M; Lee E; Tomlinson E; Scott D; Cornelius P; Patterson TA; Carpino PA Bioorg Med Chem Lett; 2012 Apr; 22(8):2738-43. PubMed ID: 22445286 [TBL] [Abstract][Full Text] [Related]
20. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives. Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]